Effect of Rivaroxaban on Fibrinolytic Therapy in Massive Pulmonary Embolism: Two Cases

被引：1

作者：

Kim, Hye-Jin ^{[1
]}

Koo, So-My ^{[1
]}

Ham, Nam-Suk ^{[1
]}

Kim, Ki-Up ^{[1
]}

Uh, Soo-Taek ^{[1
]}

Kim, Yang-Ki ^{[1
]}

机构：

[1] Soonchunhyang Univ, Coll Med, Dept Internal Med, 59 Daesagwan Ro, Seoul 140743, South Korea

来源：

TUBERCULOSIS AND RESPIRATORY DISEASES | 2014年 / 76卷 / 03期

关键词：

Pulmonary Embolism; Rivaroxaban; Fibrinolysisment;

D O I：

10.4046/trd.2014.76.3.127

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

The risk of dying from a pulmonary embolism (PE) is estimated to be about 30% if inotropic support is required and no cardiopulmonary arrest occurs. Fibrinolysis in massive PE is regarded as a life-saving intervention, unless there is a high risk of bleeding following the use of the fibrinolytic therapy. Rivaroxaban is an oral factor Xa inhibitor, however its anticoagulation effects before or after administration of fibrinolytics in massive PE are still unknown. Two patents were admitted: 61-year-old woman with repeated syncope, and a 73-year-old woman was admitted with dyspnea and poor oral intake. Systemic arterial hypotension with radiologic confirmation led to a diagnosis of massive PE in both patients. Rivaroxaban was administered before in one, and after firbrinolytic therapy in the other. One showed similar efficacy of rivaroxaban with currently used anticoagulants after successful fibrinolysis, and the other one without antecedent administration of the fibrinolytic agent showed unfavorable efficacy of rivaroxaban.

引用

页码：127 / 130

页数：4

共 5 条

[1] Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].

Bauersachs, Rupert ;

Berkowitz, Scott D. ;

Brenner, Benjamin ;

Buller, Harry R. ;

Decousus, Herve ;

Gallus, Alex S. ;

Lensing, Anthonie W. ;

Misselwitz, Frank ;

Prins, Martin H. ;

Raskob, Gary E. ;

Segers, Annelise ;

Verhamme, Peter ;

Wells, Phil ;

Agnelli, Giancarlo ;

Bounameaux, Henri ;

Cohen, Alexander ;

Davidson, Bruce L. ;

Piovella, Franco ;

Schellong, Sebastian .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510

[2] Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism [J].

Buller, Harry R. ;

Prins, Martin H. ;

Lensing, Anthonie W. A. ;

Decousus, Herve ;

Jacobson, Barry F. ;

Minar, Erich ;

Chlumsky, Jaromir ;

Verhamme, Peter ;

Wells, Phil ;

Agnelli, Giancarlo ;

Cohen, Alexander ;

Berkowitz, Scott D. ;

Bounameaux, Henri ;

Davidson, Bruce L. ;

Misselwitz, Frank ;

Gallus, Alex S. ;

Raskob, Gary E. ;

Schellong, Sebastian ;

Segers, Annelise .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14) :1287-1297

[3] Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension [J].

Jaff, Michael R. ;

McMurtry, M. Sean ;

Archer, Stephen L. ;

Cushman, Mary ;

Goldenberg, Neil ;

Goldhaber, Samuel Z. ;

Jenkins, J. Stephen ;

Kline, Jeffrey A. ;

Michaels, Andrew D. ;

Thistlethwaite, Patricia ;

Vedantham, Suresh ;

White, R. James ;

Zierler, Brenda K. .

CIRCULATION, 2011, 123 (16) :1788-1830

[4] Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines [J].

Kearon, Clive ;

Akl, Elie A. ;

Comerota, Anthony J. ;

Prandoni, Paolo ;

Bounameaux, Henri ;

Goldhaber, Samuel Z. ;

Nelson, Michael E. ;

Wells, Philip S. ;

Gould, Michael K. ;

Dentali, Francesco ;

Crowther, Mark ;

Kahn, Susan R. .

CHEST, 2012, 141 (02) :E419S-+

[5] Fibrinolysis for acute pulmonary embolism [J].

Piazza, Gregory ;

Goldhaber, Samuel Z. .

VASCULAR MEDICINE, 2010, 15 (05) :419-428

← 1 →